Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week High - Here's Why

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) reached a new 52-week high during trading on Friday . The stock traded as high as $29.47 and last traded at $29.45, with a volume of 201485 shares trading hands. The stock had previously closed at $28.02.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Enliven Therapeutics Stock Performance

The firm's 50 day moving average is $23.92 and its 200-day moving average is $22.57. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -15.53 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.17. As a group, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other news, insider Joseph P. Lyssikatos sold 12,000 shares of the firm's stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $26.70, for a total value of $320,400.00. Following the transaction, the insider now directly owns 1,093,035 shares of the company's stock, valued at approximately $29,184,034.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CFO Benjamin Hohl sold 5,250 shares of the firm's stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $26.68, for a total value of $140,070.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Joseph P. Lyssikatos sold 12,000 shares of the firm's stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $26.70, for a total transaction of $320,400.00. Following the completion of the transaction, the insider now directly owns 1,093,035 shares in the company, valued at approximately $29,184,034.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 180,409 shares of company stock valued at $4,800,526 over the last ninety days. Corporate insiders own 29.20% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC increased its position in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company's stock valued at $37,000 after acquiring an additional 742 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Enliven Therapeutics during the first quarter valued at about $167,000. SG Americas Securities LLC acquired a new stake in shares of Enliven Therapeutics during the third quarter valued at about $256,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics during the second quarter valued at about $322,000. Finally, Blackstone Inc. purchased a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $443,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.